How many longevity clinics are there in Italy?
The Atlas records 12 longevity and
preventive clinics in Italy.
Across all four pillars of the healthspan economy it
records 16 organizations in Italy, broken down below.
The Healthspan Economy Atlas records 16 organizations in Italy.
Counted from published rows only. Closed and not-yet-open organizations, and
duplicate listings, are excluded. Fertility clinics and pure booking or
telehealth platforms are mapped in the Atlas but held out of this count.
- 12
- Italy has 12 longevity and preventive medicine organizations in the Atlas.
- 2
- Italy has 2 femtech and women's health organizations in the Atlas, too few yet to read as a concentration.
- 1
- Italy has 1 integrative and functional medicine organization in the Atlas, too few yet to read as a concentration.
- 1
- Italy has 1 healthtech and diagnostics organization in the Atlas, too few yet to read as a concentration.
Verified: 16 of 16 organizations, most recent check August 25, 2026.
Where are they concentrated in Italy?
The Atlas records these city concentrations in Italy, each with
three or more organizations holding a recorded site in the city.
A further 10 organizations hold
no recorded site in any city listed above, whether because the site
is in a smaller city in Italy or because no site is on record.
Counted for the country, not shown as a concentration.
How is longevity medicine regulated in Italy?
Italy authorizes a private clinic through a national framework that the regions administer and the municipalities issue, and it confines advanced therapies prepared outside a clinical trial to public and research hospitals. No category is specific to longevity, and the national ageing law is a care and autonomy instrument rather than a longevity-medicine one.
- A private clinic is authorized under a national framework that recognizes three structure types: inpatient care, outpatient specialist care including diagnostics and laboratory work, and residential care. The municipality issues the authorization to operate, after the region verifies the project against regional need. The instrument is national, the requirements are regional, and the decision is local.
- Italian Parliament; the regions and the municipalities, Legislative Decree 502/1992, article 8-ter, inserted by Legislative Decree 229/1999 in 1999.
Primary source.
- No longevity or preventive-medicine facility category exists. The three structure types are defined by how care is delivered, as inpatient, outpatient or residential, and not by what the care is for, so a longevity clinic is authorized as an outpatient specialist facility like any other diagnostic or specialist practice.
- Italian Parliament, Legislative Decree 502/1992, article 8-ter, as checked August 2026.
Primary source.
- Advanced therapy medicinal products prepared on a non-routine basis outside a clinical trial may be used only in research and care institutes, university hospital trusts and public hospitals, and only where no valid therapeutic alternative exists or the patient's life is in danger. The Italian Medicines Agency authorizes both the production and the use. A private clinic is not an eligible setting. This is Italy's implementation of the hospital exemption the European advanced therapy regulation created.
- Ministry of Health; Agenzia Italiana del Farmaco, Ministerial Decree of January 16, 2015, citing article 28 of Regulation (EC) No 1394/2007, effective March 24, 2015.
Primary source.
- Italy's national ageing commitment rests on a real primary instrument, a 2023 delegation law and its 2024 implementing decree. Their subject is care, autonomy, social inclusion and the prevention of frailty in older people. Neither creates a clinical longevity category, a facility type, or a route to reimbursement.
- Italian Parliament, Law 33 of March 23, 2023, and Legislative Decree 29 of March 15, 2024, law in force March 31, 2023.
Primary source.
- No instrument integrates longevity or healthspan medicine into the national health service. The Italian healthspan framework reported in 2026 is a peer-reviewed perspective from a foundation and a university, and its authors present it as a staged agenda for evaluation rather than as adopted policy. It is not a government document and carries no legal effect.
- AEON Foundation; University of Bologna, Perspective in Aging, volume 18, not a government instrument, published July 16, 2026.
Primary source.
High confidence on the authorization framework and on the advanced therapy decree, both read from the consolidated law and the Gazzetta Ufficiale text. High confidence that the ageing law exists and that it is not a longevity-medicine instrument, read from the law itself. Medium confidence on the negative about a longevity facility category, which is established from the national framework and not from a sweep of every region.
This check covered the national authorization framework, the advanced therapy decree and the national ageing law. It did not check Italy's twenty regions and two autonomous provinces one by one, so a regional category naming preventive or longevity medicine cannot be ruled out from what was read. It did not cover the minimum structural and technological requirements decree, the rules that apply to wellness centers, or medical advertising.
For how Italy compares with other markets, see Longevity Clinic Regulation, Market by Market.
